Gene Expression Profiles Underlying Selective T-Cell-Mediated Immunity Activity of a Chinese Medicine Granule on Mice Infected with Influenza Virus H1N1

Table 5

Genes associated with effector T cells activation and cytokines involved in T-cell-mediated immunity.

symbol	GenBank accession	Gene description	log2 FC^a
			M/N	SH/M	SM/M	SL/M	Oseltamivir/M
Gzmb	PH_mM_0001308	Granzyme B	4.36	1.17	−4.79	−0.13	−1.54
Prf1	mMC017608	Perforin 1	2.43	0.31	−2.71	−0.55	−1.55
Fas	mMC008894	Tumor necrosis factor receptor superfamily member 6	1.70	−1.13	−1.83	−0.88	−1.70
FasL	mMC013655	Fas ligand	1.91	−1.49	−2.13	−0.08	−1.07
Il4	PH_mM_0000958	Interleukin 4, IL-4	5.43	−1.00	−5.19	−1.33	−2.64
Ifng	PH_mM_0001407	Interferon-gamma, IFN-γ	−1.02	1.28	1.23	1.38	1.35

aThe intensity ratio of probe signal criteria for differential expressions was defined as a twofold change (up or down) (log₂ ratio ≥ 1 or ≤−1) in gene expression compared with virus control group and a 𝑃 value less than 0.05 in at least one time point as a minimum requirement to select. For instance, log₂ (M/N) ≥ 1 means that the comparison between normal control group and virus control group was scattered, indicating that a large number of genes in virus control group were up-regulated in response to H1N1 infection. log₂ (SH/M) ≤ −1, log₂ (SM/M) ≤ −1, log₂ (SL/M) ≤ −1, and log₂ (Oseltamivir/M) ≤ −1 means that down-regulation in gene expression attributable to the high-dose SFXF group treatment, medium-dose SFXF group treatment, low-dose SFXF group treatment, and Oseltamivir group treatment was done by comparing genes in virus control group, respectively (𝑃 value data not shown).